Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs
The American Journal of Managed Care · 2024
DOI: 10.37765/ajmc.2024.89606 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Managed Care, 2024. Verfasst von Deborah R Kaye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Hospital, 40 Duke Medicine Circle, Durham, NC 27710. Email: deborah.kaye@duke.edu. Hauptthemen laut MEDLINE: Health Expenditures, Insurance, Health. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: The high costs of cancer care can cause significant harm to patients and society. Prostate cancer, the leading nonskin malignancy in men, is responsible for the second-highest out-of-pocket (OOP) payments among all malignancies. Multiple first-line treatment options exist for metastatic castration-resistant prostate cancer (mCRPC); although their costs vary substantially, comparative effectiveness data are limited. There is little evidence of how gross payments made by insurers and OOP payments made by patients differ by treatment and health plan type and how these payment differences relate to utilization. STUDY DESIGN: Retrospective cohort study. METHODS: We used IBM MarketScan databases from 2013-2019 to identify men with prostate cancer who initiated treatment with 1 of 6 drugs approved for first-line treatment of mCRPC. We calculated and compared gross and OOP payments and drug utilization across drug and insurance plan types. RESULTS: We identified 4298 patients who met our inclusion criteria. Insurer payments varied substantially by first-line therapy but were similar across different health plan types, except for docetaxel. OOP payments for a given first-line therapy, in contrast, varied by health plan type. Utilization of first-line therapies varied by plan type in unadjusted analyses, but not after adjusting for patient characteristics. CONCLUSIONS: The extent to which patient OOP payments for drugs reflect differences in gross payments made by insurers varies across health insurance plan types. However, even though OOP payments for the same treatment differ across plan types, treatment choice is not significantly different across type of health insurance after controlling for patient characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke University Hospital, 40 Duke Medicine Circle, Durham, NC 27710. Email: deborah.kaye@duke.edu.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Kaye, D. R., Lee, H. J., Gordee, A., George, D. J., Scales, C. D., Ubel, P. A., & Bundorf, M. K. (2024). Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2024.89606
Vancouver
Kaye DR, Lee HJ, Gordee A, George DJ, Scales CD, Ubel PA, et al. Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs. The American Journal of Managed Care. 2024. doi:10.37765/ajmc.2024.89606
BibTeX
@article{Kaye2024,
author = {Kaye, Deborah R and Lee, Hui-Jie and Gordee, Alexander and George, Daniel J and Scales, Charles D and Ubel, Peter A and Bundorf, M Kate},
title = {Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs},
journal = {The American Journal of Managed Care},
year = {2024},
doi = {10.37765/ajmc.2024.89606}
}
EUVIMED